Is your HTA strategy ready for the JCA?
The European Union’s Joint Clinical Assessment (JCA), launching in 2025, is poised to revolutionise health technology assessment (HTA) by placing greater emphasis on patient perspectives and experiences. This shift presents both challenges and opportunities for pharmaceutical companies as they navigate drug approvals in an evolving landscape. Our in-depth white paper explores the far-reaching implications of the JCA, providing actionable insights to help you adapt your HTA strategy, meaningfully engage with patients, and ultimately ensure your products are aligned with the heightened focus on patient centricity.
